Abstract 333P
Background
FDG-PET/CT and Thallium SPECT (TL) which are radioisotope examination are inspection used as diagnostic imaging in the malignant tumors conventionally, and it is reported when useful for a stage diagnosis of the lung cancer. It was common to use the CT imaging according to the RECIST criteria for the effect judgment of cytotoxic agents and molecular target agents. In determining the efficacy of immune checkpoint inhibitors (ICIs), we often experienced that the assessment on CT imaging and the true effect do not match. Therefore, we planned a prospective study to evaluate whether FDG-PET/CT and TL examination is useful for ICI effect judgment. We examined the correlation between SUV differences on PET examination before treatment and 2 months after treatment initiation and RECIST evaluation.
Methods
A total of 18 advanced NSCLC patients treated at Kansai Medical University Hospital from September 2017 to September 2018 using ICI monotherapy were enrolled in this study. We examined the correlation with a PERCIST response rate and the response rate that went to the CT evaluation using RECIST1.1.
Results
The median age was 74 years. There were 15 men and three women. 15 cases were evaluable both before and two months after treatment initiatoin. There were CR/PR/SD/PD;0/3/7/5 by RECIST evaluation, and the curative effect judgment by FDG-PET were CMR/PMR/SMD/PMD; 1/3/6/5. 1 case was PD in RECIST, but was PMR in FDG-PET.The PR case tended to be higher in Tl accumulation after the treatment than an SD and PD cases.
Conclusions
The effect measurement by FDG-PET showed usefulness with more than that of RECIST evaluation and Tl-SPECT seems to have the potential to be useful in determining the effect of ICIs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Takayasu Kurata.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract